Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PD). A second...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Jameson, M B, Thompson, P I, Baguley, B C, Evans, B D, Harvey, V J, Porter, D J, McCrystal, M R, Small, M, Bellenger, K, Gumbrell, L, Halbert, G W, Kestell, P
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2003
Aiheet:
Clinical
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2741109/
https://ncbi.nlm.nih.gov/pubmed/12799625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600992
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia